The multinational pharma company Merck has been active in Brazil for many years. Merck facts and figures. This document provides key information on the global pharmaceutical player Merck. It covers financials, strategic aspects and other KPI's as well as information on corporate responsibility topics.
Merck facts and figures. This document provides key information on the pharmaceutical player Merck. It covers financials, strategic aspects and other KPI's as well as information on corporate responsibility topics.
The skin microbiome is an emerging area of research that is transforming the cosmetics industry. Research has shown that the bacteria that make up the skin microbiome play an important role in skin health by maintaining the immune system and protecting against damage. Unbalanced microbiomes have been linked to skin conditions like eczema and acne. The cosmetics industry is developing new products containing probiotics and prebiotics that target the skin microbiome to support a balanced ecosystem. Large companies like L'Oreal and Johnson & Johnson are conducting research to increase knowledge of the skin microbiome and develop customized products tailored to individuals' microbiomes.
Merck corporate social responsibility - Merck CSR report 2012Merck-Responsibility
This is the Merck CSR report 2012. The multinational pharmaceutical company Merck provides for state-of-the-art corporate social responsibility standards and gives a comprehensive view on their CSR activities.
The pre-conference workshop will provide an interactive forum for attendees to engage with leaders on regulatory challenges surrounding biosimilars in the US and EU. The workshop will compare the EU's experience in introducing biosimilars, lessons learned, and new developments, with the recent introduction of biosimilar legislation in the US. Attendees will have the opportunity to participate in group discussions and Q&A sessions on these topics led by experts Dr. Angela Thomas of the MHRA and Dr. Anita O'Connor. The small group setting is designed to foster maximum interaction between leaders and delegates.
Biopharmaceuticals are an essential therapeutic option accounting for a substantial part of the global therapeutic market. With the patents of many blockbuster drugs coming to an end, an opportunity has arisen for the manufacture and approval of biosimilars. Visiongain\'s 9th Biosimilars Conference will look at the multiple facets of biosimilars, ranging from the evolving regulatory landscape and challenges in clinical development, to the legal and economic aspects.
This document provides information about Merck Pharmaceuticals. It begins with introductions of the instructor, group members, and team for the project. It then discusses the differences between a team and group. Next, it provides background on Merck Pharmaceuticals, including its history, founders, headquarters, values, and presence in Pakistan. It includes a mind map outlining the introduction, positioning, product positioning, improving the product line, differentiation, and conclusion. It discusses Merck's positioning strategy, priority areas of performance, people, and technology. It also outlines how product positioning can improve marketing. Finally, it provides details on Merck's product line and how it differentiates itself from competitors like Pfizer, Roche, and
Merck facts and figures. This document provides key information on the pharmaceutical player Merck. It covers financials, strategic aspects and other KPI's as well as information on corporate responsibility topics.
The skin microbiome is an emerging area of research that is transforming the cosmetics industry. Research has shown that the bacteria that make up the skin microbiome play an important role in skin health by maintaining the immune system and protecting against damage. Unbalanced microbiomes have been linked to skin conditions like eczema and acne. The cosmetics industry is developing new products containing probiotics and prebiotics that target the skin microbiome to support a balanced ecosystem. Large companies like L'Oreal and Johnson & Johnson are conducting research to increase knowledge of the skin microbiome and develop customized products tailored to individuals' microbiomes.
Merck corporate social responsibility - Merck CSR report 2012Merck-Responsibility
This is the Merck CSR report 2012. The multinational pharmaceutical company Merck provides for state-of-the-art corporate social responsibility standards and gives a comprehensive view on their CSR activities.
The pre-conference workshop will provide an interactive forum for attendees to engage with leaders on regulatory challenges surrounding biosimilars in the US and EU. The workshop will compare the EU's experience in introducing biosimilars, lessons learned, and new developments, with the recent introduction of biosimilar legislation in the US. Attendees will have the opportunity to participate in group discussions and Q&A sessions on these topics led by experts Dr. Angela Thomas of the MHRA and Dr. Anita O'Connor. The small group setting is designed to foster maximum interaction between leaders and delegates.
Biopharmaceuticals are an essential therapeutic option accounting for a substantial part of the global therapeutic market. With the patents of many blockbuster drugs coming to an end, an opportunity has arisen for the manufacture and approval of biosimilars. Visiongain\'s 9th Biosimilars Conference will look at the multiple facets of biosimilars, ranging from the evolving regulatory landscape and challenges in clinical development, to the legal and economic aspects.
This document provides information about Merck Pharmaceuticals. It begins with introductions of the instructor, group members, and team for the project. It then discusses the differences between a team and group. Next, it provides background on Merck Pharmaceuticals, including its history, founders, headquarters, values, and presence in Pakistan. It includes a mind map outlining the introduction, positioning, product positioning, improving the product line, differentiation, and conclusion. It discusses Merck's positioning strategy, priority areas of performance, people, and technology. It also outlines how product positioning can improve marketing. Finally, it provides details on Merck's product line and how it differentiates itself from competitors like Pfizer, Roche, and
This document announces the 11th Annual Biosimilars UK conference taking place October 29-31, 2012 in London. It will bring together major pharmaceutical companies, regulatory bodies, CROs, CMOs, and law firms to discuss strategies for competing in the complex biosimilars market. Key topics will include the latest regulatory guidelines, financial viability, patent strategies, approval pathways, legal issues, preclinical/clinical challenges, the roles of the US and European markets, pricing/reimbursement, and pharmacovigilance. The goal is to help participants maximize opportunities in this changing landscape. Major sponsors include Merck Millipore and United BioSource Corporation.
This document provides an overview of Venus Glucose Pvt. Ltd., an Indian pharmaceutical company. It discusses the company's history since 1989, key milestones and expansions. The company has manufacturing facilities in India and Germany, and focuses on research and development, generics, and key therapeutic areas like analgesics, antibiotics and anti-diabetics. The document also outlines the company's vision, mission and focus on developing drugs for antimicrobial resistance. It introduces the executive team and provides an organizational structure.
Lyndon Foster is a life science executive with over 30 years of experience in research, business development, and leadership. He has held roles such as Chief Operating Officer and President/Owner of his own company. He has extensive expertise in areas such as molecular biology, neuroscience, and stem cell research. Throughout his career, he has successfully led technical operations and services teams, helping companies achieve substantial growth.
8th Biosimilars Congregation 2016 conference which is taking place at 08th & 09th March 2016, The Kensington Close Hotel, Wrights Lane, London, UK.
For more details and registration simply email your interest and queries to Email – Deepak@virtueinsight.co.in
Best Regards,
Deepak Raj
Delegate and Sponsorship Sales
Virtue Insight
Gsm - + 91 9171350244
Tel - + 91 44 65515693
Skype - edeepakraj143
8th Biosimilars Congregation 2016 conference which is taking place at 08th & 09th March 2016, The Kensington Close Hotel, Wrights Lane, London, UK.
For more details and registration simply email your interest and queries to Email – Deepak@virtueinsight.co.in
Best Regards,
Deepak Raj
Delegate and Sponsorship Sales
Virtue Insight
Gsm - + 91 9171350244
Tel - + 91 44 65515693
Skype - edeepakraj143
10 Most Efficient Drug Delivery Solution Providers in 2023V2_compressed.pdfinsightscare
Insights Care’s latest edition, 10 Most Efficient Drug Delivery Solution Providers in 2023, navigates you to the rapidly changing healthcare landscape.
Krishgen is an Indian biotech company established in 2003 that focuses on developing tools for the life sciences and agri industries. It has experienced strong growth, with revenues reaching $5 million in 2011. The company provides products and services related to medical diagnostics, drug discovery research, biopharmaceuticals, and plant/food sciences.
Krishgen is an Indian biotech company established in 2003 that focuses on developing tools for the life sciences and agriculture industries. It has experienced strong growth, with revenues reaching $5 million in 2011. Krishgen provides products and services related to medical diagnostics, drug discovery research, biopharmaceuticals, and plant/food sciences. It aims to enable breakthroughs in biological research and disease treatment.
Microneedles for drug delivery patent landscape 2020 flyerKnowmade
Report’s Key Features
• PDF with > 140 slides
• Excel file > 2,450 patent families
• IP trends, including time-evolution of published patents, and countries of patent filings
• Patents’ legal status
• Ranking of main patent assignees
• Key players’ IP position and relative strength of their patent portfolios
• Summary of the IP related to applications: Cancer therapy, Cosmetic, Diabetes, Ophthalmic, Pain management and Vaccine.
• Summary of the IP related to technologies: Applicators, housing, Coated, Hollow, Porous, Soluble, Hydrogel and Solid microneedles.
• Analysis of patent oppositions (Europe) and review of key patents.
• Excel database containing all patents analyzed in the report, including applications and technologies segmentations
Krishgen is an Indian biotech company established in 2003 that focuses on medical diagnostics, drug discovery research, biopharmaceuticals, and plant/food sciences. It has experienced strong growth, with revenues reaching $5 million in 2011. Krishgen provides immunoassay kits, human cell lines, glycobiology tools, and preclinical toxicology products to support research and drug development.
The costumer experience is nowadays more important than ever for brands that want to succeed in creating a good customer-centric strategy. Consumers are demanding personalized offers and products. Brands have the opportunity to exploit digitization in order to create added value whilst capturing relevant data from their clients.
Our digital solution integrate the product features and consumer’s personal context and characteristics. The aim is to accompany consumers in a personalized manner, making the customer journey easier, and adding value.
Would you like to know how? Check out this presentation.
Merck has undergone several strategic changes over the last 10 years driven by external factors. Competitive pressures from other major pharmaceutical companies like Pfizer and GlaxoSmithKline prompted Merck to pursue acquisitions and diversify into new business areas. Regulations from government agencies also impacted Merck's marketing strategies and product liability costs. Economic conditions negatively affected revenue, requiring cost cutting measures and layoffs. Merck adapted by shifting research focus, pursuing partnerships and licenses, and targeting emerging international markets through acquisitions and new facilities.
Nutriband is a transdermal focused pharmaceutical company based in the United States with a goal to improve the safety, comfort and efficacy of existing drugs using transdermal technologies. The Company is developing a pharmaceutical pipeline to improve drug delivery technologies and capabilities for patients, physicians, and payers through transdermal delivery technologies. Nutriband’s lead product is its AVERSA® technology. AVERSA® abuse deterrent transdermal technology incorporates aversive agents to prevent the Abuse, DiVERsion, MiSuse and Accidental exposure of drugs with abuse potential, such as opioids. The Company’s first application for AVERSA® is an abuse deterrent fentanyl transdermal patch which it is developing to provide clinicians and patients a safe extended-release patch for chronic pain. The goal is to make opioid based pain treatments safe for all who need them. AVERSA technology has received patent protection in the European Union, Australia, Japan, Mexico, Russia with patent prosecution in the US and Canada. Nutriband has made sure to target all large applicable markets and its global patent protection has opened up many opportunities for the Company to make a big impact on the safety profile of drugs globally.
Dr Eckel GmbH is a leading German producer of animal feed additives with over 20 years of experience. Founded in 1994 by Dr. Antje Eckel, the company has grown significantly and now produces 20 tons of products per shift from its facility in Neiderzissen, Germany. Dr. Eckel exports its high quality additives for pigs, poultry, and ruminants worldwide. The company focuses on innovation through extensive research and product development.
The document discusses the development of mRNA therapeutics and the manufacturing challenges associated with them. Some key points:
- mRNA vaccines have advantages over traditional vaccines like speed of development and flexibility, but manufacturing challenges remain.
- Challenges include the supply of plasmid DNA, in vitro transcription processes, purification difficulties due to mRNA size/properties, and lipid nanoparticle formulation/delivery.
- Overcoming these challenges will help realize the potential of mRNA technology for a wide range of applications from mass vaccines to personalized cancer immunotherapies, which may require flexible small-batch manufacturing capabilities. Addressing production bottlenecks and developing standardized tools/processes can accelerate development.
This document provides information about the 10th Annual Conference on RNA Therapeutics taking place on February 20-21, 2019 in London. It outlines the chairs, guest speakers, and key speakers at the conference, as well as featured highlights and topics to be discussed. Some of the topics to be covered include the clinical progress of spherical nucleic acids with Exicure, Sanofi's strategies for oligonucleotide delivery, ProQR's plans for oligonucleotide supply, and the development of self-amplifying mRNA vaccines at GSK. The document provides an agenda and schedule for the two-day conference.
Ranbaxy Laboratories Limited is India's largest pharmaceutical company with a presence in 43 countries and manufacturing facilities in 8 countries. It produces affordable generic medicines and serves over 125 countries. In 2008, it entered an alliance with Daiichi Sankyo to create an innovator and generic pharmaceutical powerhouse, ranking among the top 20 global pharmaceutical companies. For 2011, it recorded global sales of $2.1 billion from both emerging and developed markets. It focuses on increasing generics business through organic and inorganic growth across geographies.
Industrial enzymes Market PPT: Trends and Dynamics, Drivers, Competitive land...IMARC Group
According to the latest report by IMARC Group,the global industrial enzymes market grew at a CAGR of 6% during 2015-2020.
Industrial enzymes are catalysts that are widely used to boost and accelerate chemical reactions across various industrial processes.
This document announces the 11th Annual Biosimilars UK conference taking place October 29-31, 2012 in London. It will bring together major pharmaceutical companies, regulatory bodies, CROs, CMOs, and law firms to discuss strategies for competing in the complex biosimilars market. Key topics will include the latest regulatory guidelines, financial viability, patent strategies, approval pathways, legal issues, preclinical/clinical challenges, the roles of the US and European markets, pricing/reimbursement, and pharmacovigilance. The goal is to help participants maximize opportunities in this changing landscape. Major sponsors include Merck Millipore and United BioSource Corporation.
This document provides an overview of Venus Glucose Pvt. Ltd., an Indian pharmaceutical company. It discusses the company's history since 1989, key milestones and expansions. The company has manufacturing facilities in India and Germany, and focuses on research and development, generics, and key therapeutic areas like analgesics, antibiotics and anti-diabetics. The document also outlines the company's vision, mission and focus on developing drugs for antimicrobial resistance. It introduces the executive team and provides an organizational structure.
Lyndon Foster is a life science executive with over 30 years of experience in research, business development, and leadership. He has held roles such as Chief Operating Officer and President/Owner of his own company. He has extensive expertise in areas such as molecular biology, neuroscience, and stem cell research. Throughout his career, he has successfully led technical operations and services teams, helping companies achieve substantial growth.
8th Biosimilars Congregation 2016 conference which is taking place at 08th & 09th March 2016, The Kensington Close Hotel, Wrights Lane, London, UK.
For more details and registration simply email your interest and queries to Email – Deepak@virtueinsight.co.in
Best Regards,
Deepak Raj
Delegate and Sponsorship Sales
Virtue Insight
Gsm - + 91 9171350244
Tel - + 91 44 65515693
Skype - edeepakraj143
8th Biosimilars Congregation 2016 conference which is taking place at 08th & 09th March 2016, The Kensington Close Hotel, Wrights Lane, London, UK.
For more details and registration simply email your interest and queries to Email – Deepak@virtueinsight.co.in
Best Regards,
Deepak Raj
Delegate and Sponsorship Sales
Virtue Insight
Gsm - + 91 9171350244
Tel - + 91 44 65515693
Skype - edeepakraj143
10 Most Efficient Drug Delivery Solution Providers in 2023V2_compressed.pdfinsightscare
Insights Care’s latest edition, 10 Most Efficient Drug Delivery Solution Providers in 2023, navigates you to the rapidly changing healthcare landscape.
Krishgen is an Indian biotech company established in 2003 that focuses on developing tools for the life sciences and agri industries. It has experienced strong growth, with revenues reaching $5 million in 2011. The company provides products and services related to medical diagnostics, drug discovery research, biopharmaceuticals, and plant/food sciences.
Krishgen is an Indian biotech company established in 2003 that focuses on developing tools for the life sciences and agriculture industries. It has experienced strong growth, with revenues reaching $5 million in 2011. Krishgen provides products and services related to medical diagnostics, drug discovery research, biopharmaceuticals, and plant/food sciences. It aims to enable breakthroughs in biological research and disease treatment.
Microneedles for drug delivery patent landscape 2020 flyerKnowmade
Report’s Key Features
• PDF with > 140 slides
• Excel file > 2,450 patent families
• IP trends, including time-evolution of published patents, and countries of patent filings
• Patents’ legal status
• Ranking of main patent assignees
• Key players’ IP position and relative strength of their patent portfolios
• Summary of the IP related to applications: Cancer therapy, Cosmetic, Diabetes, Ophthalmic, Pain management and Vaccine.
• Summary of the IP related to technologies: Applicators, housing, Coated, Hollow, Porous, Soluble, Hydrogel and Solid microneedles.
• Analysis of patent oppositions (Europe) and review of key patents.
• Excel database containing all patents analyzed in the report, including applications and technologies segmentations
Krishgen is an Indian biotech company established in 2003 that focuses on medical diagnostics, drug discovery research, biopharmaceuticals, and plant/food sciences. It has experienced strong growth, with revenues reaching $5 million in 2011. Krishgen provides immunoassay kits, human cell lines, glycobiology tools, and preclinical toxicology products to support research and drug development.
The costumer experience is nowadays more important than ever for brands that want to succeed in creating a good customer-centric strategy. Consumers are demanding personalized offers and products. Brands have the opportunity to exploit digitization in order to create added value whilst capturing relevant data from their clients.
Our digital solution integrate the product features and consumer’s personal context and characteristics. The aim is to accompany consumers in a personalized manner, making the customer journey easier, and adding value.
Would you like to know how? Check out this presentation.
Merck has undergone several strategic changes over the last 10 years driven by external factors. Competitive pressures from other major pharmaceutical companies like Pfizer and GlaxoSmithKline prompted Merck to pursue acquisitions and diversify into new business areas. Regulations from government agencies also impacted Merck's marketing strategies and product liability costs. Economic conditions negatively affected revenue, requiring cost cutting measures and layoffs. Merck adapted by shifting research focus, pursuing partnerships and licenses, and targeting emerging international markets through acquisitions and new facilities.
Nutriband is a transdermal focused pharmaceutical company based in the United States with a goal to improve the safety, comfort and efficacy of existing drugs using transdermal technologies. The Company is developing a pharmaceutical pipeline to improve drug delivery technologies and capabilities for patients, physicians, and payers through transdermal delivery technologies. Nutriband’s lead product is its AVERSA® technology. AVERSA® abuse deterrent transdermal technology incorporates aversive agents to prevent the Abuse, DiVERsion, MiSuse and Accidental exposure of drugs with abuse potential, such as opioids. The Company’s first application for AVERSA® is an abuse deterrent fentanyl transdermal patch which it is developing to provide clinicians and patients a safe extended-release patch for chronic pain. The goal is to make opioid based pain treatments safe for all who need them. AVERSA technology has received patent protection in the European Union, Australia, Japan, Mexico, Russia with patent prosecution in the US and Canada. Nutriband has made sure to target all large applicable markets and its global patent protection has opened up many opportunities for the Company to make a big impact on the safety profile of drugs globally.
Dr Eckel GmbH is a leading German producer of animal feed additives with over 20 years of experience. Founded in 1994 by Dr. Antje Eckel, the company has grown significantly and now produces 20 tons of products per shift from its facility in Neiderzissen, Germany. Dr. Eckel exports its high quality additives for pigs, poultry, and ruminants worldwide. The company focuses on innovation through extensive research and product development.
The document discusses the development of mRNA therapeutics and the manufacturing challenges associated with them. Some key points:
- mRNA vaccines have advantages over traditional vaccines like speed of development and flexibility, but manufacturing challenges remain.
- Challenges include the supply of plasmid DNA, in vitro transcription processes, purification difficulties due to mRNA size/properties, and lipid nanoparticle formulation/delivery.
- Overcoming these challenges will help realize the potential of mRNA technology for a wide range of applications from mass vaccines to personalized cancer immunotherapies, which may require flexible small-batch manufacturing capabilities. Addressing production bottlenecks and developing standardized tools/processes can accelerate development.
This document provides information about the 10th Annual Conference on RNA Therapeutics taking place on February 20-21, 2019 in London. It outlines the chairs, guest speakers, and key speakers at the conference, as well as featured highlights and topics to be discussed. Some of the topics to be covered include the clinical progress of spherical nucleic acids with Exicure, Sanofi's strategies for oligonucleotide delivery, ProQR's plans for oligonucleotide supply, and the development of self-amplifying mRNA vaccines at GSK. The document provides an agenda and schedule for the two-day conference.
Ranbaxy Laboratories Limited is India's largest pharmaceutical company with a presence in 43 countries and manufacturing facilities in 8 countries. It produces affordable generic medicines and serves over 125 countries. In 2008, it entered an alliance with Daiichi Sankyo to create an innovator and generic pharmaceutical powerhouse, ranking among the top 20 global pharmaceutical companies. For 2011, it recorded global sales of $2.1 billion from both emerging and developed markets. It focuses on increasing generics business through organic and inorganic growth across geographies.
Industrial enzymes Market PPT: Trends and Dynamics, Drivers, Competitive land...IMARC Group
According to the latest report by IMARC Group,the global industrial enzymes market grew at a CAGR of 6% during 2015-2020.
Industrial enzymes are catalysts that are widely used to boost and accelerate chemical reactions across various industrial processes.
Similar to Merck Brazil - Facts and Figures of Merck Pharmaceutical Company in Brazil (20)
Anny Serafina Love - Letter of Recommendation by Kellen Harkins, MS.AnnySerafinaLove
This letter, written by Kellen Harkins, Course Director at Full Sail University, commends Anny Love's exemplary performance in the Video Sharing Platforms class. It highlights her dedication, willingness to challenge herself, and exceptional skills in production, editing, and marketing across various video platforms like YouTube, TikTok, and Instagram.
Unveiling the Dynamic Personalities, Key Dates, and Horoscope Insights: Gemin...my Pandit
Explore the fascinating world of the Gemini Zodiac Sign. Discover the unique personality traits, key dates, and horoscope insights of Gemini individuals. Learn how their sociable, communicative nature and boundless curiosity make them the dynamic explorers of the zodiac. Dive into the duality of the Gemini sign and understand their intellectual and adventurous spirit.
Industrial Tech SW: Category Renewal and CreationChristian Dahlen
Every industrial revolution has created a new set of categories and a new set of players.
Multiple new technologies have emerged, but Samsara and C3.ai are only two companies which have gone public so far.
Manufacturing startups constitute the largest pipeline share of unicorns and IPO candidates in the SF Bay Area, and software startups dominate in Germany.
The Most Inspiring Entrepreneurs to Follow in 2024.pdfthesiliconleaders
In a world where the potential of youth innovation remains vastly untouched, there emerges a guiding light in the form of Norm Goldstein, the Founder and CEO of EduNetwork Partners. His dedication to this cause has earned him recognition as a Congressional Leadership Award recipient.
[To download this presentation, visit:
https://www.oeconsulting.com.sg/training-presentations]
This PowerPoint compilation offers a comprehensive overview of 20 leading innovation management frameworks and methodologies, selected for their broad applicability across various industries and organizational contexts. These frameworks are valuable resources for a wide range of users, including business professionals, educators, and consultants.
Each framework is presented with visually engaging diagrams and templates, ensuring the content is both informative and appealing. While this compilation is thorough, please note that the slides are intended as supplementary resources and may not be sufficient for standalone instructional purposes.
This compilation is ideal for anyone looking to enhance their understanding of innovation management and drive meaningful change within their organization. Whether you aim to improve product development processes, enhance customer experiences, or drive digital transformation, these frameworks offer valuable insights and tools to help you achieve your goals.
INCLUDED FRAMEWORKS/MODELS:
1. Stanford’s Design Thinking
2. IDEO’s Human-Centered Design
3. Strategyzer’s Business Model Innovation
4. Lean Startup Methodology
5. Agile Innovation Framework
6. Doblin’s Ten Types of Innovation
7. McKinsey’s Three Horizons of Growth
8. Customer Journey Map
9. Christensen’s Disruptive Innovation Theory
10. Blue Ocean Strategy
11. Strategyn’s Jobs-To-Be-Done (JTBD) Framework with Job Map
12. Design Sprint Framework
13. The Double Diamond
14. Lean Six Sigma DMAIC
15. TRIZ Problem-Solving Framework
16. Edward de Bono’s Six Thinking Hats
17. Stage-Gate Model
18. Toyota’s Six Steps of Kaizen
19. Microsoft’s Digital Transformation Framework
20. Design for Six Sigma (DFSS)
To download this presentation, visit:
https://www.oeconsulting.com.sg/training-presentations
NIMA2024 | De toegevoegde waarde van DEI en ESG in campagnes | Nathalie Lam |...BBPMedia1
Nathalie zal delen hoe DEI en ESG een fundamentele rol kunnen spelen in je merkstrategie en je de juiste aansluiting kan creëren met je doelgroep. Door middel van voorbeelden en simpele handvatten toont ze hoe dit in jouw organisatie toegepast kan worden.
Storytelling is an incredibly valuable tool to share data and information. To get the most impact from stories there are a number of key ingredients. These are based on science and human nature. Using these elements in a story you can deliver information impactfully, ensure action and drive change.
Digital Marketing with a Focus on Sustainabilitysssourabhsharma
Digital Marketing best practices including influencer marketing, content creators, and omnichannel marketing for Sustainable Brands at the Sustainable Cosmetics Summit 2024 in New York
Call8328958814 satta matka Kalyan result satta guessing➑➌➋➑➒➎➑➑➊➍
Satta Matka Kalyan Main Mumbai Fastest Results
Satta Matka ❋ Sattamatka ❋ New Mumbai Ratan Satta Matka ❋ Fast Matka ❋ Milan Market ❋ Kalyan Matka Results ❋ Satta Game ❋ Matka Game ❋ Satta Matka ❋ Kalyan Satta Matka ❋ Mumbai Main ❋ Online Matka Results ❋ Satta Matka Tips ❋ Milan Chart ❋ Satta Matka Boss❋ New Star Day ❋ Satta King ❋ Live Satta Matka Results ❋ Satta Matka Company ❋ Indian Matka ❋ Satta Matka 143❋ Kalyan Night Matka..
The Steadfast and Reliable Bull: Taurus Zodiac Signmy Pandit
Explore the steadfast and reliable nature of the Taurus Zodiac Sign. Discover the personality traits, key dates, and horoscope insights that define the determined and practical Taurus, and learn how their grounded nature makes them the anchor of the zodiac.
How are Lilac French Bulldogs Beauty Charming the World and Capturing Hearts....Lacey Max
“After being the most listed dog breed in the United States for 31
years in a row, the Labrador Retriever has dropped to second place
in the American Kennel Club's annual survey of the country's most
popular canines. The French Bulldog is the new top dog in the
United States as of 2022. The stylish puppy has ascended the
rankings in rapid time despite having health concerns and limited
color choices.”
[To download this presentation, visit:
https://www.oeconsulting.com.sg/training-presentations]
This presentation is a curated compilation of PowerPoint diagrams and templates designed to illustrate 20 different digital transformation frameworks and models. These frameworks are based on recent industry trends and best practices, ensuring that the content remains relevant and up-to-date.
Key highlights include Microsoft's Digital Transformation Framework, which focuses on driving innovation and efficiency, and McKinsey's Ten Guiding Principles, which provide strategic insights for successful digital transformation. Additionally, Forrester's framework emphasizes enhancing customer experiences and modernizing IT infrastructure, while IDC's MaturityScape helps assess and develop organizational digital maturity. MIT's framework explores cutting-edge strategies for achieving digital success.
These materials are perfect for enhancing your business or classroom presentations, offering visual aids to supplement your insights. Please note that while comprehensive, these slides are intended as supplementary resources and may not be complete for standalone instructional purposes.
Frameworks/Models included:
Microsoft’s Digital Transformation Framework
McKinsey’s Ten Guiding Principles of Digital Transformation
Forrester’s Digital Transformation Framework
IDC’s Digital Transformation MaturityScape
MIT’s Digital Transformation Framework
Gartner’s Digital Transformation Framework
Accenture’s Digital Strategy & Enterprise Frameworks
Deloitte’s Digital Industrial Transformation Framework
Capgemini’s Digital Transformation Framework
PwC’s Digital Transformation Framework
Cisco’s Digital Transformation Framework
Cognizant’s Digital Transformation Framework
DXC Technology’s Digital Transformation Framework
The BCG Strategy Palette
McKinsey’s Digital Transformation Framework
Digital Transformation Compass
Four Levels of Digital Maturity
Design Thinking Framework
Business Model Canvas
Customer Journey Map
2. OUR FIELDS:
PHARMACEUTICALS. CHEMICALS. LIFE SCIENCE.
PHARMACEUTICALS: We discover, develop, manufacture and commercialize
innovative prescription drugs and therapies for high unmet medical needs.
Through their targeted effect, these help patients to live a longer and better
life (Merck Serono).
In addition, for the consumer health care market, we offer a wide range
of over-the-counter products that help prevent illness and relieve minor
complaints (Consumer Health).
At Merck, around 39,000 people in 66 countries develop pharmaceutical, chem-
ical and life science innovations. We operate our businesses in four divisions:
Merck Serono, Consumer Health, Performance Materials and Merck Millipore.
3_013_FACTS+FIGURES_EN.indd 2 13.03.13 15:0
3. CHEMICALS: Our broad range of specialty chemicals are used in
technologically sophisticated applications ranging from liquid crystal
mixtures for flat-panel displays, to effect pigments and cosmetic
ingredients (Performance Materials).
LIFE SCIENCE: As a leading global partner to this future-oriented industry,
we offer products, applications and solutions for protein research and
cell biology as well as for the manufacture of chemical and biopharma-
ceutical drugs. Our products and services range from laboratory chemi-
cals, reagents and consumables to analytical methods and laboratory
water purification systems (Merck Millipore).
CE.
3_013_FACTS+FIGURES_EN.indd 3 13.03.13 15:0
5. We are convinced that in our core pharmaceutical, chemical and life science
businesses, the market will reward successful research and technological
advances with attractive margins. Our focus is on innovative specialty prod-
ucts. Competing on price alone and operating in commodity markets is not
what we do.
We have a clear objective: profitable growth. This is based on a distinct,
fundamental strategy that can be summed up in three words: Sustain.
Change. Grow. It’s a strategy based on the right balance between the old
and the new, between tradition and innovation. It gives us the best possible
preconditions for future growth and makes it possible to fully unleash our
entrepreneurial potential.
Our strategy and our ethical company values give our employees clear
orientation for their daily work. We enable them to share in the company’s
success and, thus, also in the execution risk. This way, we will remain
curious and courageous – and continue to seize many new opportunities
in the future.
3_013_FACTS+FIGURES_EN.indd 5 13.03.13 15:0
7. MERCK SERONO:
EFFECTIVE MEDICINES TO FIGHT
DAUNTING OPPONENTS.
Merck Serono is the largest division of Merck and focuses on specialist
therapeutic areas such as oncology, multiple sclerosis, growth disorders,
and infertility. The division offers innovative prescription drugs of chemical
and biological origin.
We are proud of our innovative products – and we invest around € 1 billion
in R&D every year in our core therapeutic areas Oncology, Multiple Sclerosis
and Immunology.
Endocrinology: Saizen® (growth hormone disorders),
Serostim® (HIV-associated wasting),
Kuvan® (metabolic disorder hyperphenylalaninemia),
Egrifta™ (HIV-associated lipodystrophy)
General Medicine: Glucophage® franchise (type 2 diabetes),
Concor® franchise (cardiovascular diseases),
Euthyrox® (thyroid disorders)
3_013_FACTS+FIGURES_EN.indd 7 13.03.13 15:0
8. Mobility:
Products to strengthen the joints and relieve pain, including the brands
Seven Seas® and Kytta®
Cough and cold:
Cold treatment Nasivin® (Iliadin®); Sedalmerck® for pain relief
KEY ProDUCTS:
3_013_FACTS+FIGURES_EN.indd 8 13.03.13 15:0
9. CONSUMER HEALTH:
PREVENTING MINOR AILMENTS
AND PROTECTING HEALTH.
Everyday health protection:
Probiotic multivitamin products from the Bion® and Multibionta® ranges
Vitamins and minerals sold under brand names such as Cebion® and Diabion®
Women’s and children’s health:
Femibion®, products with folic acid and Metafolin® for pregnant and
nursing women; Kidabion® (Haliborange®), a vitamin product range for
children; Sangobion® for iron deficiency
Many consumers around the world trust a wide range of well-known brands
with scientifically based mechanisms of action that Merck develops, manu-
factures and markets for the OTC (over-the-counter) pharmaceutical sec-
tor. Our focus in the Consumer Health division is on eight strategic brands,
specializing in key aspects of health care, such as mobility, everyday health
protection, women’s health, cough and cold, and allergies. Our scientifically
based product portfolio is aligned to the needs of consumers worldwide.The
main distribution channels are pharmacies, as well as retail chains, drugstores
and mail order in some countries.
3_013_FACTS+FIGURES_EN.indd 9 13.03.13 15:0
10. KEY ProDUCTS:
licristal® Liquid crystal mixtures for displays
Isiphor® Lighting materials for energy-efficient, high-quality LED lighting
livilux® Materials for OLEDs (organic light-emitting diodes)
isishape® Efficient, eco-friendly materials for structuring solar cells and
touchscreens
3_013_FACTS+FIGURES_EN.indd 10 13.03.13 15:0
11. PERFORMANCE MATERIALS:
LCDs, EFFECT PIGMENTS AND MORE.
Merck is the global leader in the liquid crystals market. Liquid crystals are
used throughout the world, in LCD TVs, monitors, tablet computers, notebooks,
and mobile phones. In addition, the Performance Materials division focuses
on materials for energy-saving lighting using LEDs (light-emitting diodes) and
OLEDs (organic LEDs) as well as for OLED smartphone displays.
Pigments for the coatings, plastics and printing industries as well as for
cosmetic applications are an important part of the Performance Materials
portfolio. Moreover, the division is the market leader for pearl luster effect
pigments – a highly specialized niche within the pigment market.
Iriodin®, Xirallic ®, Colorstream ®
Effect pigments for use in coatings, packaging and product design
Timiron®, Colorona®, Ronaflair ®, Xirona®
Effect and functional pigments for cosmetic formulations
Ronacare®
Cosmetic active ingredients for skin care
3_013_FACTS+FIGURES_EN.indd 11 13.03.13 15:0
12. Products for life science research in the pharmaceutical and biotechnology
industries
Products for protein research and cell biology including consumables,
reagents and services to help customers better understand diseases and
biological functions
KEY ProDUCTS:
3_013_FACTS+FIGURES_EN.indd 12 13.03.13 15:0
13. MERCK MILLIPORE:
PRODUCTS AND SERVICES FOR PHARMA-
CEUTICAL RESEARCH AND BIOTECHNOLOGY.
With the Merck Millipore division, Merck is a leading life science tools
company. The portfolio comprises products and services for the life science
industry such as assays, biomarkers and target solutions, as well as biopro-
cessing, lab water purification and filtration. These are used by customers
working in research and analytical laboratories as well as in pharmaceutical
manufacturing. Additionally, the division supplies specialty chemicals mainly
to regulated markets, for example the pharmaceutical, cosmetics and food
industries. Analytical and scientific laboratories use the reagents and test kits
supplied by the division. The Merck Millipore portfolio comprises more than
60,000 products and processes.
Laboratory chemicals and materials for research, science and industry
Products and services for sampling and assay platforms for the pharmaceutical,
food and diagnostics industries
Products, consumables and services for ultrapure laboratory water in science
and industry
Products that help to develop and manufacture pharmaceutical and biopharma-
ceutical drugs safely and efficiently
3_013_FACTS+FIGURES_EN.indd 13 13.03.13 15:0
15. • Extended indication of the multiple sclerosis drug Rebif® was approved
in Europe in 2012 for use in patients who have experienced a single
demyelinating event, an early sign of the disease.
• The targeted oncology drug Erbitux® is currently approved for use in colo-
rectal cancer in 92 countries and in head and neck cancer in 90 countries.
• Merck Serono researchers are currently working on 16 projects in
drug development.
• With innovative liquid crystal mixtures for polymer-stabilized vertical
alignment (PS-VA) applications, we further expanded our technology lead-
ership. PS-VA technology opens up new possibilities for LCD producers to
achieve previously unattained screen properties.
• Organic light-emitting diodes (OLEDs) convert electricity most efficiently
into light and can be produced as thin, flexible films. Application possibilities
include displays, for example in mobile phones or small televisions.
• With Scepter™, the Merck Millipore division launched the world’s first auto-
mated handheld cell counter.
• For photovoltaics, Merck supplies materials for the cost-efficient production
of solar cells and develops new materials, e.g. for flexible, organic solar cells.
• Merck is working on innovative lighting materials, such as those for
power-saving white LEDs, which may represent an alternative to conventional
incandescent light bulbs and energy-saving lamps.
3_013_FACTS+FIGURES_EN.indd 15 13.03.13 15:0
16. Karl-Ludwig Kley, Chairman
Born in 1951, lawyer
Member of the Merck Supervisory Board and Board of Partners
from March 2004 to June 2006; on the Merck Executive Board
since September 2006.
Responsible for Group functions:
Group Strategy, Group Communications, Group Legal
and Compliance, Group Internal Auditing
MERCK MANAGEMENT:
THE MEMBERS OF THE EXECUTIVE BOARD.
Kai Beckmann, Head of Human Resources /
Chief Administration Officer
Born in 1965, university degree in computer science
Joined Merck in 1989; on the Merck Executive Board
since April 2011.
Responsible for Group functions:
Group Human Resources, Group Information Services,
Site Operations, Inhouse Consulting
Stefan Oschmann,
responsible for the Merck Serono
and Consumer Health divisions
Born in 1957, veterinarian
On the Merck Executive Board since January 2011.
Responsible for Group functions:
Patents Scientific Services
3_013_FACTS+FIGURES_EN.indd 16 13.03.13 15:0
17. Bernd Reckmann,
responsible for the Performance Materials
and Merck Millipore divisions
Born in 1955, biochemist
Joined Merck in 1986; on the Merck Executive Board
since January 2007.
Responsible for Group functions:
Environment, Health, Safety, Security, Quality
Matthias Zachert, Chief Financial Officer
Born in 1967, university degree in business
On the Merck Executive Board since June 2011.
Responsible for Group functions:
Group Accounting Subsidiaries, Group Controlling Risk
Management, Corporate Finance, Group Tax, Group Insurance,
Group Procurement, Investor Relations
3_013_FACTS+FIGURES_EN.indd 17 13.03.13 15:0
18. MERCK AT A GLANCE:
KEY FIGURES FOR 2012.
MERCK ONLINE:
SERVICE LINKS.
In 2012, the Merck Group generated total revenues of € 11.2 billion.
The Merck Serono division accounted for € 6.4 billion, the Consumer Health
division for € 475 million, the Performance Materials division for € 1.7 billion
and the Merck Millipore division for € 2.6 billion of that total. EBITDA pre,
with which the earning power of operating activities is measured, climbed to
€ 3 billion.
Research and development spending amounted to € 1.5 billion. The operating
result totaled € 964 million and free cash flow was € 2 billion.
Important and current information on the company can be found on the Web at
www.merckgroup.com
The following websites offer information on special topics:
www.merckgroup.com/darmstadt, www.merckgroup.com/investors,
www.merckgroup.com/history, www.merckgroup.com/responsibility,
www.merckgroup.com/innovations
Up-to-date articles and reports on Merck, its fields of activity and products can be found at:
www.merckgroup.com/explorermagazine
Brochures and audiovisual media on Merck’s activities can be ordered from
Group Communications or downloaded from www.merckgroup.com/publications
3_013_FACTS+FIGURES_EN.indd 18 13.03.13 15:0
19. Total revenues by division (in € million)
Sales by region (in € million)
Operating result by division* (in € million)
North America
2,128
Consumer Health
475
Consumer Health
4
Merck Serono
6,405
Merck Serono
508
Merck Millipore
2,617
Merck Millipore
233
Performance Materials
1,676
Performance Materials
599
Emerging Markets
3,712
Europe
3,943
Rest of World
958
*excluding Corporate and Other
m
m
pm
ch
Ser
mm
pm
ch
Ser
Rest
EmergMa
NA
EU
3_013_FACTS+FIGURES_EN.indd 19 13.03.13 15:0
20. The Merck Group. An overview.
Published in March 2013
by Merck KGaA, Group Communications,
Frankfurter Strasse 250, 64293 Darmstadt, Germany
Phone: +49 (0) 6151-72 0
Fax: +49 (0) 6151-72 5577
E-mail: comms@merckgroup.com
Website: www.merckgroup.com
Photos: Robert Wilson, Torben Conrad
Concept and design: Nissen Carstensen GmbH
Lithography: data-graphis GmbH
Printing: Frotscher Druck GmbH, Darmstadt
W 840 103
3_013_FACTS+FIGURES_EN.indd 20 13.03.13 15:0